Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 1

1(20.0%)

Phase 2

1(20.0%)

5Total

N/A(3)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07075328Phase 1Recruiting

A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma

Role: lead

NCT05326230Not ApplicableActive Not Recruiting

A Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO)

Role: lead

NCT04719637Not ApplicableCompleted

Clinical Study of an Ultrasound Renal Denervation System in Patients With Heart Failure

Role: lead

NCT06589505Phase 2Recruiting

Software as a Medical Device for the Treatment of Patients With PTSD

Role: lead

NCT05759819Not ApplicableActive Not Recruiting

Evaluate the Efficacy and Safety of the Cilostazol-coated BioMimics 3D Stent System in Patients with Peripheral Arterial Occlusive Disease

Role: lead

All 5 trials loaded